Clinical Trials

FDA Delays Review of Neurotech’s Eye Implant for Macular Telangiectasia
Research & Development FDA Delays Review of Neurotech’s Eye Implant for Macular Telangiectasia

In a strategic move aimed at ensuring the utmost safety and efficacy, the US Food and Drug Administration (FDA) has recently announced a three-month delay in the priority review of Neurotech Pharmaceuticals' NT-501 eye cell therapy implant. This extension shifts the anticipated action date to

MD Anderson Launches Institute for Pioneering Cell Therapy Research
Research & Development MD Anderson Launches Institute for Pioneering Cell Therapy Research

The University of Texas MD Anderson Cancer Center has unveiled its ambitious new initiative, the Institute for Cell Therapy Discovery & Innovation, fueled by an impressive initial funding of over $80 million. This pioneering institute aims to revolutionize the realms of immunology and cell

Global Cell Culture Vessels Market to Reach $19.65B by 2033
Management & Regulatory Global Cell Culture Vessels Market to Reach $19.65B by 2033

The global cell culture vessels market is on a remarkable growth trajectory, projected to expand from an estimated USD 4.90 billion in 2023 to over USD 19.65 billion by 2033. This significant growth, at a robust CAGR of 14.9% from 2024 to 2033, underscores the critical role of cell culture

Rising Breast Cancer Rates Among Indian Women Aged 55-64 Demand Action
Research & Development Rising Breast Cancer Rates Among Indian Women Aged 55-64 Demand Action

Breast Cancer Awareness Month has highlighted a pressing health crisis among Indian women, particularly those aged 55 to 64. A recent report by Healthians reveals that 16% of women in this demographic are affected by breast cancer. This alarming statistic underscores the urgent need for awareness,

AbbVie Faces Setback as Schizophrenia Drug Fails Clinical Trials
Research & Development AbbVie Faces Setback as Schizophrenia Drug Fails Clinical Trials

The pharmaceutical industry is no stranger to challenges and setbacks, especially in the area of neurological and psychiatric treatments. AbbVie, a multinational biopharmaceutical company, recently faced a significant hurdle when its promising schizophrenia drug, emraclidine, failed to meet

Gene Therapy Investment Falls Post-COVID, Showing Future Hope
Management & Regulatory Gene Therapy Investment Falls Post-COVID, Showing Future Hope

The gene therapy sector, once a beacon of hope for revolutionary treatments, has seen a significant slowdown in investment post the COVID-19 pandemic. This downturn follows a period of unprecedented financial influx during the pandemic years, raising questions about the future of this promising

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later